Skin Cancer

The FDA has granted priority review to Merck’s application for pembrolizumab, a treatment for melanoma.

Researchers from UT Southwestern Medical Center have investigated a new way to use AI to determine the metastatic potential of melanoma.

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.

Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.

In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).

In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

St. Jude Children’s Research Hospital researchers have created a registry to better understand pediatric melanoma.

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma.

OncoSec Medical Inc. and Merck have entered into a supply and clinical trial agreement for pembrolizumab (Keytruda) and tavokinogene telseplasmid (Tavo) for the potential treatment of late-stage metastatic melanoma.

DermTech offers a new way to detect skin cancer without patients having to go under the knife.

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

New regulations, latest absorption data, and updates on environmental and health impacts are shaping the world of photoprotection.

Christopher Bunick, MD, PhD, associate professor of dermatology, Yale University and Dermatology Times® editorial advisory board member, weighs in on a recent report revealing certain batches of various sunscreen and after-sun care products were contaminated with benzene, a carcinogen.

David Light, founder and CEO of Valisure, the independent lab that discovered the presence of benzene in multiple brands and batches of sunscreen, sits down with Dermatology Times to discuss the reports' findings and the impact this news will have on the sun protection industry.

A recent test found various brands and batches of sunscreen and after-sun care products contained benzene, a potential carcinogen.

Content-aware image restoration (CARE) technology demonstrated improvement in examining cellular details of skin.

A study published in JAMA Dermatology investigated how consumers look at sunscreen active ingredients in response to an FDA proposed rule.

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events.

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

In this video interview, Melissa Stenstrom, MD, discusses how physicians can promote the use of sun protection and regular skin cancer screenings to help prevent skin cancer among their patients.

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

Treatment pairing dabrafenib and trametinib could have expanded benefits for patients with melanoma.

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.